UTR Therapeutics plans to initiate a Phase 1 trial of UTRxM1-18 in patients with advanced c-MYC–driven tumors pending regulatory approvals. The company is also exploring translational and commercial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback